Bellus hit with a setback as its PhII chronic cough drug flops on all 4 doses — shares cremated on Wall Street
Bellus Health says their Phase II study for a new drug to treat chronic cough failed, but they already lined up Plan B to help …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
